uPath Ki-67 (30-9) image analysis, Breast
Use left and right arrow keys to scroll between the tabs
uPath whole slide image analysis algorithms
An intelligent and advanced digital pathology solution requires artificial intelligence-based image analysis tools that empower pathologists to confidently and objectively assess whole tissue slide images.
The uPath Ki-67 (30-9) image analysis, Breast algorithm* is an adjunctive computer-assisted tool that identifies Ki-67 positive and negative tumor cells within a pathologist annotated viable tumor region in images of formalin-fixed, paraffin-embedded neoplastic breast tissue.
Prioritizing accuracy and precision for enhanced slide review
Integrated and ready-to-use
Validated for use with the CONFIRM Ki-67 (30-9) Antibody and navify Digital Pathology
Quick and automated
Pathologist-trained deep learning algorithm quickly identifies Ki-67 tumor cell positivity.
Accurate, consistent and confident
Actionable assessment of slide images that are objective and reproducible.1
Efficiency and convenience: the Roche uPath Ki-67 (30-9) image analysis algorithm*
- Enhance accuracy for research purposes with a pathologist-trained deep learning algorithm which results in objective and reproducible scoring of slide images scanned on a VENTANA DP 200 or a VENTANA DP 600 slide scanner and stained with the CONFIRM anti-Ki-67 (30-9) Rabbit Monoclonal Primary Antibody1
- Fully embedded into navify Digital Pathology to enable seamless viewing, aligning, syncing, sharing, and reporting
- Speed up time to results for user-defined regions of interest with whole slide analysis (WSA) and automated pre-computing of the slide image prior to pathologist assessment1
- Quickly identify Ki-67 tumor cell positivity
- A clear visual overlay highlights tumor cells with and without nuclear staining for easy reference
Specifications
| Scanner | VENTANA DP 200 and VENTANA DP 600 slide scanners |
| Software | navify Digital Pathology |
| Algorithm | uPath Ki-67 (30-9) image analysis, Breast* |
| Assay | CONFIRM anti-Ki-67 (30-9) Rabbit Monoclonal Primary Antibody |
| Tissue Type | Breast |
| Scoring | Ki67 positivity |
| Regulatory status | Research Use Only (RUO) |
Maximize the potential of your digital pathology laboratory
The Roche Digital Pathology solution comprises high-performance hardware, software and uPath whole slide image analysis algorithms, and works in integrated harmony with the full Roche diagnostic portfolio for an end-to-end experience that enhances pathology workflows.
*For research use only. Not for use in diagnostic procedures.
Roche Digital Pathology Dx, including navify Digital Pathology, is intended for specific clinical applications and is for research and educational use for other applications. Please review the product labeling for compliance before utilization.
NAVIFY and VENTANA and UPATH are trademarks of Roche. Other product names and trademarks are the property of their respective owners.
Reference:
- Kapadia, M., et al. (2022). "Abstract P1-02-17: Artificial intelligence-based whole slide scoring of nuclear breast cancer IHC markers Ki67, ER, and PR matches performance of manual clinical scoring." Cancer Research 82(4_Supplement): P1-02-17. https://doi.org/10.1158/1538-7445.SABCS21-P1-02-17.
